120 related articles for article (PubMed ID: 24315309)
21. Targeting CD46 Enhances Anti-Tumoral Activity of Adenovirus Type 5 for Bladder Cancer.
Do MH; To PK; Cho YS; Kwon SY; Hwang EC; Choi C; Cho SH; Lee SJ; Hemmi S; Jung C
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30201920
[TBL] [Abstract][Full Text] [Related]
22. Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma.
Liu Y; Ye T; Sun D; Maynard J; Deisseroth A
Hum Gene Ther; 2004 Jul; 15(7):637-47. PubMed ID: 15242524
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor receptor targeting of replication competent adenovirus enhances cytotoxicity in bladder cancer.
van der Poel HG; Molenaar B; van Beusechem VW; Haisma HJ; Rodriguez R; Curiel DT; Gerritsen WR
J Urol; 2002 Jul; 168(1):266-72. PubMed ID: 12050554
[TBL] [Abstract][Full Text] [Related]
24. [Gene expression of tumor cells both in vitro and in vivo enhanced by integrin-targeting adenovirus vector].
Gao JQ; Chen HL; Nakagawa S; Mizuguchi H; Liang WQ
Yao Xue Xue Bao; 2006 Nov; 41(11):1116-20. PubMed ID: 17262958
[TBL] [Abstract][Full Text] [Related]
25. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency.
Wu H; Seki T; Dmitriev I; Uil T; Kashentseva E; Han T; Curiel DT
Hum Gene Ther; 2002 Sep; 13(13):1647-53. PubMed ID: 12228019
[TBL] [Abstract][Full Text] [Related]
26. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.
Ramesh N; Ge Y; Ennist DL; Zhu M; Mina M; Ganesh S; Reddy PS; Yu DC
Clin Cancer Res; 2006 Jan; 12(1):305-13. PubMed ID: 16397056
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of transfection rates on head and neck squamous cell cancer by a novel adenovirus: an in vivo and in vitro study.
Lalonde ES; Beyer G; Friedlander PL; Kolls JK
Head Neck; 2002 Dec; 24(12):1038-46. PubMed ID: 12454941
[TBL] [Abstract][Full Text] [Related]
28. Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer.
Zhai Z; Wang Z; Fu S; Lu J; Wang F; Li R; Zhang H; Li S; Hou Z; Wang H; Rodriguez R
Gene Ther; 2012 Nov; 19(11):1065-74. PubMed ID: 22218302
[TBL] [Abstract][Full Text] [Related]
29. Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer.
Sachs MD; Rauen KA; Ramamurthy M; Dodson JL; De Marzo AM; Putzi MJ; Schoenberg MP; Rodriguez R
Urology; 2002 Sep; 60(3):531-6. PubMed ID: 12350512
[TBL] [Abstract][Full Text] [Related]
30. Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression.
You Z; Fischer DC; Tong X; Hasenburg A; Aguilar-Cordova E; Kieback DG
Cancer Gene Ther; 2001 Mar; 8(3):168-75. PubMed ID: 11332987
[TBL] [Abstract][Full Text] [Related]
31. Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA.
Kim J; Nam HY; Kim TI; Kim PH; Ryu J; Yun CO; Kim SW
Biomaterials; 2011 Aug; 32(22):5158-66. PubMed ID: 21531456
[TBL] [Abstract][Full Text] [Related]
32. Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors.
Borovjagin AV; Krendelchtchikov A; Ramesh N; Yu DC; Douglas JT; Curiel DT
Cancer Gene Ther; 2005 May; 12(5):475-86. PubMed ID: 15706356
[TBL] [Abstract][Full Text] [Related]
33. Fetal muscle gene transfer is not enhanced by an RGD capsid modification to high-capacity adenoviral vectors.
Bilbao R; Reay DP; Hughes T; Biermann V; Volpers C; Goldberg L; Bergelson J; Kochanek S; Clemens PR
Gene Ther; 2003 Oct; 10(21):1821-9. PubMed ID: 12960972
[TBL] [Abstract][Full Text] [Related]
34. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model.
Melquist JJ; Kacka M; Li Y; Malaeb BS; Elmore J; Baseman AG; Hsieh JT; Koeneman KS
Urol Oncol; 2006; 24(4):362-71. PubMed ID: 16818192
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
36. A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression.
Cao W; Tian J; Li C; Gao Y; Liu X; Lu J; Wang Y; Wang Z; Svatek RS; Rodriguez R
Virol J; 2017 Aug; 14(1):149. PubMed ID: 28789701
[TBL] [Abstract][Full Text] [Related]
37. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
[TBL] [Abstract][Full Text] [Related]
38. Efficient gene transfer by fiber-mutant adenoviral vectors containing RGD peptide.
Koizumi N; Mizuguchi H; Hosono T; Ishii-Watabe A; Uchida E; Utoguchi N; Watanabe Y; Hayakawa T
Biochim Biophys Acta; 2001 Nov; 1568(1):13-20. PubMed ID: 11731080
[TBL] [Abstract][Full Text] [Related]
39. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells.
Shirakawa T; Hamada K; Zhang Z; Okada H; Tagawa M; Kamidono S; Kawabata M; Gotoh A
Clin Cancer Res; 2004 Jul; 10(13):4342-8. PubMed ID: 15240520
[TBL] [Abstract][Full Text] [Related]
40. Increased antitumor capability of fiber-modified adenoviral vector armed with TRAIL against bladder cancers.
Zhao Y; Li Y; Wang Q; Wang L; Yang H; Li M
Mol Cell Biochem; 2011 Jul; 353(1-2):93-9. PubMed ID: 21437625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
